Pargyline (hydrochloride) (Synonyms: NSC 43798) |
| رقم الكتالوجGC16824 |
Pargyline (هيدروكلوريد) هو مثبط لا رجعة فيه مونوامين أوكسيديز (MAO) مع Kis من 13 ميكرومتر و 0.5 ميكرومتر لـ MAO-A و MAO-B ، على التوالي.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 306-07-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 11.52 nM: inhibits monoamine oxidase (MAO) type A (MAO-A).
IC50: 8.2 nM: blocks MAO type B (MAO-B).
Pargyline, an irreversible and non-selective inhibitor of MAO, is used to treat moderate hypertension and cancer cells. There are two isoforms of MAO, MAO-A and MAO-B. MAO-A preferentially deaminates melatonin, serotonin, norepinephrine and epinephrine. MAO-B catalyzes the oxidative deamination and inactivation of certain catecholamines within the presynaptic nerve terminals.
In vitro: Pargyline reduced the proliferation of human prostate carcinoma (LNCaP-LN3) cells in a time- and dose-dependent fashion. In addition, compared to the control, pargyline remarkably triggered cell cycle arrest at the G1 phase. Pargyline elicited an increase in the cell death rate via promoting apoptosis, suggesting that pargyline was a powerful candidate drug for the treatment of human prostate cancer [1].
In vivo: Male rats were injected intraperitoneally pargyline at a dose of 75 mg/kg for 80 min. Pargyline significantly increased the concentration of extracellular dopamine in the striatum and simultaneously, significantly reduced the concentration of extracellular MAO-derived metabolite 3,4-dihydroxyphenylacetic acid to undetectable levels [2].
References:
[1]. Chai, Y. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncology Reports. 2013.
[2]. Desvignes, C., Bert, L., Vinet, L., Denoroy, L., Renaud, B., & Lambás-Seas, L. Evidence that the neuronal nitric oxide synthase inhibitor 7-nitroindazole inhibits monoamine oxidase in the rat: in vivo effects on extracellular striatal dopamine and 3,4-dihydroxyphenylacetic acid. Neuroscience Letters. 1999; 261(3):175-178.
| Cas No. | 306-07-0 | SDF | |
| المرادفات | NSC 43798 | ||
| Chemical Name | N-methyl-N-2-propynyl-benzenemethanamine, monohydrochloride | ||
| Canonical SMILES | CN(CC#C)CC1=CC=CC=C1.Cl | ||
| Formula | C11H13N • HCl | M.Wt | 195.7 |
| الذوبان | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 5mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 5.1099 mL | 25.5493 mL | 51.0986 mL |
| 5 mM | 1.022 mL | 5.1099 mL | 10.2197 mL |
| 10 mM | 0.511 mL | 2.5549 mL | 5.1099 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *